.Attributes Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of individuals with HER2+ sophisticated breast cancer cells as well as active or even dependable human brain metastases revealed constant intracranial task and also wide spread effectiveness of T-DXd.